TARTARIC ACID
Molecular Excipient
| Mwt. | LogP | HBD | HBA | PSA | RB | CSP3 |
|---|---|---|---|---|---|---|
| 148.0 | -4.8 | 2 | 6 | 121.0 | 3 | 0.5 |
- CAS
- 87694
- UNII
- W4888I119H
- SYNONYMS
-
- ZINC ID(s)
- Availability
- Present in 114 ZINC catalogs
Known Active Genes
This compound has been observed to have activity at 10μM or less against the following gene(s).
| Name | Description | Classification |
|---|---|---|
| GBA | Glucosylceramidase | Enzyme / Enzyme-Other |
Clinical Trials
This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
| Code | Date | Title | Phase | Status |
|---|---|---|---|---|
| NCT02023866 | 2014-06-01 | Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease | Phase 2/Phase 3 | Recruiting |
| NCT01749982 | 2012-12-01 | A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh | Phase 4 | Completed |
| NCT01529268 | 2012-06-01 | Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children | Phase 2/Phase 3 | Active, Not Recruiting |
| NCT01197378 | 2010-08-01 | Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) | Phase 3 | Active, Not Recruiting |
| NCT01149538 | 2010-07-01 | Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure | Phase 1/Phase 2 | Completed |
| NCT01000961 | 2010-06-01 | Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis | Phase 3 | Completed |
| NCT02170896 | 2001-10-01 | Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects | Phase 1 | Completed |
(Browse) Purchasable Analogs in ZINC
Functions of Tartaric Acid
| Misc - Miscellaneous |
Regulatory Status of Tartaric Acid
| Gras - Generally recognized as safe. |
Dosages
| Route | Formulation | Per Unit Dose |
|---|---|---|
| Intramuscular | Injection | 0.35% |
| Intravenous | Injectable | 0.5% |
| Intravenous | Injection | 2% |
| Intravenous | Powder, For Injection Solution, Lyophilized | 2% |
| Intravenous | Solution, Injection | 0.2% |
| Iv(Infusion) | Injection | 2% |
| Iv(Infusion) | Powder, For Injection Solution, Lyophilized | 2% |
| Oral | Capsule | 177.14MG |
| Oral | Capsule, Extended Release | 132.52MG |
| Oral | Capsule, Sustained Action | 215.1MG |
| Oral | Powder, For Solution | 1.1GM |
| Oral | Solution | 0.76%W/W |
| Oral | Suspension | 0.2% |
| Oral | Tablet | 15MG |
| Oral | Tablet, Coated | 10MG |
| Oral | Tablet, Extended Release | 75MG |
| Oral | Tablet, Film Coated | 30MG |
| Oral | Tablet, Orally Disintegrating | 45MG |
| Oral | Tablet, Sustained Action | 29.2MG |
| Subcutaneous | Solution, Injection | 0.15% |
| Sublingual | Tablet | |
| Topical | Film, Controlled Release | |
| Topical | Patch | |
| Topical | Patch, Controlled Release |